swerte live99
Michael Croley | (TNS) Bloomberg News In the old days of 2016, when golfers visited the Dormie Club in West End, North Carolina — 15 minutes from the hotbed of American golf, Pinehurst — they were greeted by a small, single-wide trailer and a rugged pine straw parking lot. Related Articles Travel | A preview of some stunning hotels and resorts opening in 2025 Travel | Travel scams that can hurt your credit or finances Travel | Travel: Paddle the Loxahatchee River, one of two National Wild and Scenic Rivers in Florida Travel | 7 family-friendly ski resorts in the US that won’t break the bank Travel | It’s beginning to look like another record for holiday travel That trailer is now long gone. A gate has been installed at the club’s entrance and a long driveway leads to a grand turnaround that sweeps you past a new modern clubhouse that’s all right angles, with floor-to-ceiling glass. Seconds after you exit your car, valets are zipping up in golf carts, taking your name, then your bags, handing you keys to your own golf cart, and then zipping off to drop your luggage in the four-bedroom cottage where you’ll stay. A short walk past an expansive putting green you’ll find the pro shop — and then you’ll see the club’s most elegant feature: its golf course. The changes have all come about because Dormie Club was acquired in 2017 by the Dormie Network, a national group that owns seven private golf facilities from Nebraska to New Jersey. (“Dormie” is a word for being ahead in golf — the names were coincidences.) A key to the network’s success has been its ability to find clubs ripe for acquisition, with outstanding golf courses and existing on-site lodging or the room to build it, says Zach Peed, president of the company and its driving force. After investing in Arbor Links Golf Club in Nebraska City, Nebraska, in late 2015, Peed believed he saw an opening in the golf market: a new model of hospitality for traveling professionals who wanted a pure golf experience that eschewed the pools and pickleball courts of their home clubs. His clubs would become dream golf-only getaways for avid players and their pals. “Dormie Network’s concept was sparked by having played competitive golf in college, combined with an element of experiencing and understanding hospitality,” says Peed. “It made sense to blend the two to create golf trips that had more value than just playing golf. We want genuine hospitality to help create unforgettable memories and new friendships.” Part of that formula has been in the lodging strategy; in North Carolina, 15 four-bedroom cottages now are a short golf cart ride from the main clubhouse. In each, golfers all have their own king-size bed and en suite bathroom. A large common room is dominated by a flatscreen television along with a well-stocked bar and snacks. That ability to be both social, or tucked away in your room, extends to the expansive new clubhouse, where a high-ceilinged bar area with blond wood creates an inviting space for dining and drinking, and several hideaway rooms allow for more private diners with just your group. So far, their commitment to hospitality has been helping them expand in both membership and club usage in the increasingly competitive market for traveling golfers. Major players such as Bandon Dunes, Pinehurst Resort, and the Cabot Collection have created — or renovated — a new paradigm where golfers get dining and lodging that’s as showcase-worthy as the courses they play. Comfortable sheets and options beyond pub food aren’t luxuries anymore, but staples for many group trips. Dormie has answered that call by focusing on both the big details and the small ones, like having the dew wiped off each golf cart at dawn outside guest cottages before the day begins or having a tray of cocktails delivered to golfers as their final putt falls on the 18th green. These touches may seem over-the-top, but they stand out in a world where golf travel is increasingly popular — and expensive — after the pandemic lockdowns. Since 2020 there has been an explosion in participation in the sport, with new golfers picking up the game and avid golfers playing more: According to the National Golf Foundation, a record 531 million rounds were played in 2023, surpassing the high of 529 million set in 2021. Supreme Golf, a public golf booking website, reports in its latest analysis that the average cost of a tee time has increased to $49 in 2024 from $38 in 2019, a 30% increase. Those cost increases are also on par (pun intended) with the costs of private clubs and initiation fees during that same period, where membership rosters that were dwindling pre-COVID now have waitlists 50 to 60 people deep, according to Jason Becker, co-founder and chief executive officer of Golf Life Navigators, which matches homebuyers with golf course communities. “There’s been an absolute run on private golf. If we use southwest Florida as an example, where there are 158 golf communities, this time last November, only five had memberships available,” he said. That inability to find a club close to home has pushed avid golfers to look farther afield, choosing national memberships at clubs that require traveling, usually via plane, to play. Dormie has capitalized on this growing segment, offering two types of memberships: First, a national membership, where members pay an initiation fee and monthly dues just as they would at a local club, but instead of one club they have access to seven. The second option is a signature membership for companies, “which allows businesses to use our properties for entertainment needs and requires a multiyear commitment,” Peed says. The network also offers a limited number of regional memberships for those living within a certain distance of one of its clubs. Dormie Network declined to provide the cost of memberships or monthly dues and wouldn’t give membership numbers, but the clubs are structured to lodge roughly 60 golfers, max, on-site at any given property at any time. The total number of beds across the network’s portfolio of properties has increased from 84 in 2019 to 432 today. It saw a jump from 10,000 room nights in 2019 to 48,000 in 2023. This September, Dormie opened GrayBull in Maxwell, in Nebraska’s, Sandhills region. Dormie Network tabbed David McLay Kidd to build the course, who also built the original course at Oregon’s famed Bandon Dunes. Kidd says of the property GrayBull sits on, “It’s like the Goldilocks thing: not too flat, not too steep. It’s kind of in a bowl that looks inwards, and there are no bad views.” That kind of remote destination, where the long-range views are only Mother Nature or other golf holes, is what drives many traveling golfers these days. Peed says his team leaned on years of knowledge from Dormie’s acquisitions as they built GrayBull, which started construction in 2022. “We had an understanding of how our members and guests use the clubs that allowed us to take a blank canvas in the Sandhills of Nebraska and combine all of the greatest aspects of each Dormie property into one.” ©2024 Bloomberg L.P. Visit bloomberg.com. Distributed by Tribune Content Agency, LLC.
SACRAMENTO, Calif. (AP) — California, home to some of the largest technology companies in the world, would be the first U.S. state to require mental health warning labels on social media sites if lawmakers pass a bill introduced Monday. The legislation sponsored by state Attorney General Rob Bonta is necessary to bolster safety for children online, supporters say, but industry officials vow to fight the measure and others like it under the First Amendment. Warning labels for social media gained swift bipartisan support from dozens of attorneys general, including Bonta, after U.S. Surgeon General Vivek Murthy called on Congress to establish the requirements earlier this year, saying social media is a contributing factor in the mental health crisis among young people. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Dione Protocol Announces DIONE SPARK: A Grants & Accelerator Program to Propel Green Web3 Innovation
Lawyer says ex-Temple basketball standout Hysier Miller met with NCAA for hours amid gambling probeAnthony Weiner, ex-congressman jailed in sexting scandal, files to run for NYC City Council seat
Systemic Sclerosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight 12-26-2024 04:21 PM CET | Health & Medicine Press release from: DelveInsight Business Research Systemic Sclerosis Clinical Trials (New York, USA) DelveInsight's, "Systemic Sclerosis Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Systemic Sclerosis pipeline landscape. It covers the Systemic Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Request a sample and discover the recent advances in Systemic Sclerosis Treatment Drugs @ Systemic Sclerosis Pipeline Report- https://www.delveinsight.com/report-store/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr In the Systemic Sclerosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Systemic Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Key Takeaways from the Systemic Sclerosis Pipeline Report • DelveInsight's Systemic Sclerosis pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Systemic Sclerosis treatment. • Leading Systemic Sclerosis companies working in the Market include Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Pfizer, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences, and others. • Promising Systemic Sclerosis Pipeline Therapies in the various stages of development include GS-248, KHK4827, Paquinimod, Inebilizumab, Nemolizumab, RO7303509, Treprostinil Diethanolamine, and others. • On September 2023, Horizon Pharma Ltd announced a study of phase 2 clinical trials for HZN-825 BID. All participants who complete the Double-blind Treatment Period (Week 52) will be eligible to enter a 52-week extension trial (HZNP-HZN-825-302, NCT05626751). Participants not entering the extension trial will participate in a Safety Follow-up Visit 4 weeks after the last dose of trial drug. • On September 2023, Hospital for Special Surgery, New York announced a study of phase 2 clinical trials for Belimumab, and MMF. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either Belimumab & Rituximab or placebo. Patients in both groups will be on background MMF for the entirety of the study. Belimumab will be administered subcutaneously and Rituximab intravenously. Systemic Sclerosis Overview Scleroderma, also known as Systemic Sclerosis, progressive systemic sclerosis or the CREST syndrome, is a chronic skin disorder that affects the skin, connective tissues and other internal organs. The disorder takes place sin humans, when the immune system causes the body to make the protein collagen, an important component of the skin, in huge amounts. Find out more about Systemic Sclerosis Therapeutics Assessment @ Systemic Sclerosis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr Systemic Sclerosis Emerging Drugs Profile • Iloprost: Eicos Sciences • ECCS 50: Cytori therapeutics • Lenabasum (JBT-101): Corbus Pharmaceuticals • EHP-101: Emerald Health Pharmaceuticals Systemic Sclerosis Pipeline Therapeutics Assessment There are approx. 50+ key companies which are developing the Systemic Sclerosis therapies. The Systemic Sclerosis companies which have their Systemic Sclerosis drug candidates in the most advanced stage, i.e. Phase III include, Eicos Sciences. Learn more about the emerging Systemic Sclerosis Pipeline Therapies @ Systemic Sclerosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr Scope of the Systemic Sclerosis Pipeline Report • Coverage- Global • Systemic Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination • Systemic Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III • Systemic Sclerosis Companies- Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Pfizer, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences, and others. • Systemic Sclerosis Pipeline Therapies- GS-248, KHK4827, Paquinimod, Inebilizumab, Nemolizumab, RO7303509, Treprostinil Diethanolamine, and others. Dive deep into rich insights for new drugs for Systemic Sclerosis Treatment Market, Visit @ Systemic Sclerosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr Table of Content 1. Introduction 2. Executive Summary 3. Systemic Sclerosis: Overview 4. Pipeline Therapeutics 5. Therapeutic Assessment 6. Late Stage Products (Phase III) 7. Iloprost: Eicos Sciences 8. Drug profiles in the detailed report..... 9. Mid Stage Products (Phase II) 10. EHP-101: Emerald Health Pharmaceuticals 11. Drug profiles in the detailed report..... 12. Early stage products (Phase I) 13. VIB7734: Viela Bio 14. Drug profiles in the detailed report..... 15. Inactive Products 16. Systemic Sclerosis Key Companies 17. Systemic Sclerosis Key Products 18. Systemic Sclerosis- Unmet Needs 19. Systemic Sclerosis- Market Drivers and Barriers 20. Systemic Sclerosis- Future Perspectives and Conclusion 21. Systemic Sclerosis Analyst Views 22. Systemic Sclerosis Key Companies 23. Appendix For further information on the Systemic Sclerosis pipeline therapeutics, reach out to Systemic Sclerosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/systemic-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr Trending Reports: •Rhino Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-rhino-conjunctivitis-market •Sialidosis Market: https://www.delveinsight.com/report-store/sialidosis-market •Stable Angina Market: https://www.delveinsight.com/report-store/stable-angina-market •Thymic Carcinoma Market: https://www.delveinsight.com/report-store/thymus-cancer-market •Turner Syndrome Market: https://www.delveinsight.com/report-store/turner-syndrome-market •Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/ventricular-fibrillation-market •Waiha Market: https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market •Wegener S Granulomatosis/granulomatosis With Polyangiitis Market: https://www.delveinsight.com/report-store/wegeners-granulomatosis-market Contact Us: Ankit Nigam Manager Marketing info@delveinsight.com +14699457679 https://www.delveinsight.com/asco-conference-coverage About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. This release was published on openPR.
AP Sports SummaryBrief at 5:24 p.m. ESTHere's an interesting stocking stuffer to consider ... and it's a blast from the past, literally. A radioactive atomic energy lab kit complete with real uranium is hitting the auction block ... and it's considered the world's most dangerous toy. Officially known as the Gilbert U-238 Atomic Energy Laboratory, the toy is from the early 1950s -- back when atomic bombs were relatively new -- and it was marketed as an educational toy for budding scientists. The toy lab kit was created by Alfred Carlton Gilbert ... the same guy who came up with the iconic Erector Set. RR Auction says fewer than 5,000 of these puppies were ever made ... making this a super rare find. The toy was discontinued in 1951, with Gilbert's company blaming "government restrictions" and the "difficulty of obtaining materials." The toy has real uranium, after all. Here's what's included in the lab kit ... a cloud chamber for viewing alpha particles, a spinthariscope to observe radioactive disintegration and an electroscope to measure radiation levels in the four included substances ... carnotite, autunite, torbernite, and uraninite. The kit also has some extras ... including a U.S. government guide to uranium prospecting. Make no mistake, the uranium samples are radioactive ... but a 2020 analysis by IEEE Spectrum, the world's leading engineering magazine, says the radiation is equivalent to UV exposure from the sun ... at least as long as the samples remain in the sealed containers. Bidding ends Dec. 11 ... just in time for the holidays.
A multibillion-dollar plan to create “clean” hydrogen from brown coal and ship it to Japan is on the brink of collapse, according to Japanese media reports suggesting that Kawasaki Heavy Industries has withdrawn from the trial, blaming procurement delays. The controversial plan was billed as a lifeline for the Latrobe Valley’s ageing brown coal industry. Under the plan, hydrogen would be extracted from coal, creating the world’s first liquefied hydrogen supply chain. Kawasaki Heavy Industries has reportedly withdrawn from plan to create “clean” hydrogen from brown coal sourced from the Latrobe Valley. Credit: Eamon Gallagher Proponents said the joint venture, led by Japan’s largest industrial conglomerates, would use commercially unproven CO2 capture and storage technology to sequester carbon in the Bass Strait. It was also to send the super-cooled hydrogen extracted from coal in purpose-built bulk carriers out of Hastings to Kawasaki in the Asian nation’s industrial heartland. The Hydrogen Energy Supply Chain project (HESC) was a partnership between international fossil energy companies, including Kawasaki Heavy Industries Ltd (KHI), Royal Dutch Shell and AGL. Japanese outlet Nikkei reported that Kawasaki Heavy Industries had abandoned its bid to establish an international supply chain to procure hydrogen from Australia because it had become “difficult to procure hydrogen in Australia within the deadline”. “With the completion of the demonstration test by fiscal year 2030, as originally scheduled, being an absolute requirement for ensuring competitiveness, the company has changed hydrogen procurement to domestic,” Nikkei reported. “It has also downsized its hydrogen carriers and is now steering toward a more ‘realistic’ solution.” Victorian Energy Minister Lily D’Ambrosio raised doubts about the project last year at an Australian Financial Review Energy and Climate Summit, saying it was not clear that the proponents would be able to adequately capture the carbon from the coal and safely sequester it. “That is a question that is yet to be answered,” she said. The AFR reported that Kawasaki Heavy Industries’ chairman Yoshinori Kanehana told a separate event last year that his business had been focused on winning “social license” from Victorian communities and hoped to avoid “ideological divides”. Friends of the Earth gas campaigner Freja Leonard said Kawasaki Heavy Industries’ decision to withdraw indicated the project wasn’t financially or practically feasible. “It’s just an absolute nonsense to use brown coal in a climate crisis to produce hydrogen,” she said. “Hydrogen is notoriously difficult to contain. It’s incredibly expensive to produce, and any project that expects to successfully ship hydrogen from one country to another without significant leakage is doomed to failure.” A commercial-in-confidence report on the proposal compiled by the Department of Industry, Science and Resources in 2022 and released under freedom of information laws argued the plan was broadly supported in the Latrobe Valley. “There are a limited number of groups within the Latrobe Valley that do not support the use of fossil fuels and are against CCS [carbon capture and storage],” it stated. “However, the predominant sentiment in the Valley is one that supports the HESC [Hydrogen Energy Supply Chain].” Identifying challenges getting stakeholders like the local council on board, the report noted that the HESC had “revised [its] messaging”, “highlighting the carbon neutrality” the project could achieve by combining biomass with coal. This, it said, “softens the image of HESC as a coal-driven project”. Under the plan, the cooled hydrogen would have been piped more than 150 kilometres from Gippsland to the Port of Hastings and shipped to Japan. In January 2022, according to the confidential report, hydrogen was successfully generated under trial from brown coal and biomass. However, it reported cost overruns and lengthy delays to the trial. More to come Get to the heart of what’s happening with climate change and the environment. Sign up for our fortnightly Environment newsletter.